The role of pathologist in the diagnosis and treatment of melanoma is pivotal to optimal patient care. With so many disciplines relying on the...

Cancer drugs have rapidly evolved in the last decade. Alongside the significant benefits are new toxicity profiles that clinicians need to be aware of...

In this presentation, A/Prof Andrew Haydon reviews the efficacy data from 6 large-scale Phase III studies that are looking at the use of modern...

In this presentation, A/Prof Sydney Ch’ng discovers the current recommendations for sentinel node biopsy and the implications of high-risk Stage II melanoma trial findings....

With up to 14% of patients developing in-transit disease and biologically diverse pathobiological behaviour is observed, in-transit disease is a significant clinical burden. In...

Immune checkpoint inhibitors have revolutionised care for patients with advanced melanoma, with around half of patients with unresectable metastatic melanoma living to five years...

In this presentation given at the Yale School of Medicine Dermatology Grand Rounds, world-leading melanoma pathologist, Prof Richard Scolyer AO, discusses: • MIA’s goals...

The field of melanoma has experienced a paradigm shift in recent years, with advancements in both diagnosis and management driving improved patient outcomes. Through...

‘To shave or not to shave, that is the question.’ In this engaging debate, Dermatologist A/Prof Victoria Mar and Surgeon Prof Michael Henderson present...